1/23
08:04 am
cort
Rating for CORT
Medium
Report
Rating for CORT
1/2
08:05 am
cort
Rating for CORT
Medium
Report
Rating for CORT
1/2
07:18 am
cort
Corcept Therapeutics (NASDAQ:CORT) had its "buy" rating reaffirmed by analysts at HC Wainwright.
Medium
Report
Corcept Therapeutics (NASDAQ:CORT) had its "buy" rating reaffirmed by analysts at HC Wainwright.
12/31
10:00 am
cort
Corcept Therapeutics (NASDAQ:CORT) was downgraded by analysts at Wolfe Research from a "peer perform" rating to an "underperform" rating. They now have a $30.00 price target on the stock.
Medium
Report
Corcept Therapeutics (NASDAQ:CORT) was downgraded by analysts at Wolfe Research from a "peer perform" rating to an "underperform" rating. They now have a $30.00 price target on the stock.
12/31
10:00 am
cort
Corcept Therapeutics (NASDAQ:CORT) was downgraded by analysts at Wolfe Research from a "peer perform" rating to an "underperform" rating. They now have a $30.00 price target on the stock.
Medium
Report
Corcept Therapeutics (NASDAQ:CORT) was downgraded by analysts at Wolfe Research from a "peer perform" rating to an "underperform" rating. They now have a $30.00 price target on the stock.
12/31
09:47 am
cort
Corcept Therapeutics downgraded to Underperform from Peer Perform at Wolfe Research
Medium
Report
Corcept Therapeutics downgraded to Underperform from Peer Perform at Wolfe Research
12/31
09:47 am
cort
Corcept Therapeutics downgraded to Underperform from Peer Perform at Wolfe Research
Medium
Report
Corcept Therapeutics downgraded to Underperform from Peer Perform at Wolfe Research
12/18
07:06 am
cort
Corcept Therapeutics (NASDAQ:CORT) was upgraded by analysts at UBS Group AG to a "hold" rating.
Low
Report
Corcept Therapeutics (NASDAQ:CORT) was upgraded by analysts at UBS Group AG to a "hold" rating.
12/16
08:38 am
cort
Rating for CORT
Medium
Report
Rating for CORT
12/16
06:05 am
cort
Corcept Therapeutics (NASDAQ:CORT) is now covered by analysts at UBS Group AG. They set a "neutral" rating on the stock.
Medium
Report
Corcept Therapeutics (NASDAQ:CORT) is now covered by analysts at UBS Group AG. They set a "neutral" rating on the stock.
12/16
05:11 am
cort
Corcept Therapeutics initiated with a Neutral at UBS
Medium
Report
Corcept Therapeutics initiated with a Neutral at UBS